Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/9947
Title: | Small cell Carcinomas of the bladder highly express somatostatin receptor type 2A: Impact on prognosis and treatment-a multicenter study of urooncology society, Turkey | Authors: | Nese, N. Kumbaraci, B.S. Baydar, D.E. Kilicaslan, I. Sari, A.A. Sen, S. Gonul, I.I. |
Keywords: | Bladder Cancer Small cell carcinoma Somatostatin receptor SSTR-2A somatostatin derivative somatostatin receptor somatostatin receptor 1 somatostatin receptor 2A somatostatin receptor 3 somatostatin receptor 4 somatostatin receptor 5 unclassified drug somatostatin receptor 2 tumor marker adult aged Article bladder cancer bladder small cell carcinoma cancer prognosis cancer survival cancer therapy clinical article clinical feature female histopathology human human tissue immunohistochemistry immunoreactivity male priority journal protein expression small cell carcinoma transitional cell carcinoma Turkey (republic) bladder tumor clinical trial metabolism middle aged multicenter study prognosis very elderly Adult Aged Aged, 80 and over Biomarkers, Tumor Carcinoma, Small Cell Female Humans Immunohistochemistry Male Middle Aged Prognosis Receptors, Somatostatin Urinary Bladder Neoplasms |
Publisher: | Lippincott Williams and Wilkins | Abstract: | Small cell carcinoma (SmCC) is a rare and aggressive neuroendocrine carcinoma of the bladder. Neuroendocrine carcinomas expressing somatostatin receptors (SSTR) in other viscera such as lung, pancreas, and gastrointestinal system respond to therapy with somatostatin analogs. In the present study, expressions of SSTRs 1 to 5 including type 2A are investigated by immunohistochemistry (IHC) and their relationship with clinicopathologic factors was evaluated. Hundred primary bladder SmCC cases were collected from 12 centers in Turkey. Forty-three cases were pure SmCC. Other cases had mostly papillary urothelial carcinoma as a second component. The percentage of the SmCC component ranged from 5% to 100%. SSTR-2A expression was membranous, whereas the other receptors showed cytoplasmic staining. The percentages of positive cases for SSTR-1, SSTR-2A, SSTR-3, SSTR-4, and SSTR-5 were 4% (3/75), 61.4% (54/88), 2.4% (2/84), 24.4% (20/82), and 6.25% (5/80), respectively. The percentage of SmCC component was positively correlated with the percentage of SSTR-2A expression (P=0.003) while negatively correlated with patient age (P=0.032). SSTR-2A expression was correlated with survival as a bad prognostic factor (P=0.018). SSTR-1, SSTR-3, SSTR-4, and SSTR-5 expressions did not show any statistical significance with any parameter. In conclusion, although the limited number of cases with adequate term follow-up, SSTR-2A expression could be a prognostic factor and somatostatin analogs therapeutic candidate for SmCCs of the bladder as these tumors show high percentage of SSTR-2A expression. © 2016 Wolters Kluwer Health, Inc. All rights reserved. | URI: | https://hdl.handle.net/11499/9947 https://doi.org/10.1097/PAI.0000000000000188 |
ISSN: | 1541-2016 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
5
checked on Nov 23, 2024
WEB OF SCIENCETM
Citations
3
checked on Nov 22, 2024
Page view(s)
46
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.